Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Rhea-AI Summary
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company specializing in treatments for hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA), has announced its participation in the Bank of America Securities 2025 Health Care Conference. The event will be held in Las Vegas from May 12-15, 2025.
The company's management will deliver a presentation on Wednesday, May 14, 2025, at 4:35 PM PDT. Investors can access a live webcast of the presentation through the Investor Relations section of Mineralys' website. The presentation recording will remain available for approximately 90 days on the company's website.
Positive
- None.
Negative
- None.
News Market Reaction – MLYS
On the day this news was published, MLYS gained 2.07%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025.
| Bank of America Securities Health Care Conference | ||
| Date: | Wednesday, May 14, 2025 | |
| Time: | 4:35pm PDT | |
| Format: | Presentation | |
| Webcast Link | ||
A live webcast of the presentation can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the presentation will be available on the Company’s website for approximately 90 days.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
When is Mineralys Therapeutics (MLYS) presenting at the Bank of America Securities Health Care Conference 2025?
What diseases does Mineralys Therapeutics (MLYS) focus on treating?
How can investors access Mineralys Therapeutics' (MLYS) presentation at the BofA Healthcare Conference?
Where is the Bank of America Securities 2025 Health Care Conference being held?
